NAUT - Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. is currently listed on NASDAQ under NAUT. One share of NAUT stock can currently be purchased for approximately $2.16. Is Nautilus Biotechnology, Inc. listed on the NASDAQ ...
Model output · Signal date 2026-10-16
Nautilus Biotechnology, Inc. (NAUT) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Top 35%
of 5172 stocks scored
Rank correlation · 90D
8.0%
Spearman, 357 dates
Market Cap
$262M
small-cap · #14 of 25 peers
Summary
Nautilus Biotechnology, Inc. (NAUT) stock forecast summary
Our AI ranks Nautilus Biotechnology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Nautilus Biotechnology, Inc. is a small-cap company with a market capitalization of $262M. It ranks number 14 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
For NAUT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 8.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NAUT included.
Follow NAUT freePrice
NAUT price chart and AI forecast
Cross-section · 2026-10-16
How NAUT ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Nautilus Biotechnology, Inc. (NAUT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | NAUT | Rank |
|---|---|---|
| Market Cap | $262M | 14/25 |
| P/B Ratio | 2.00x | 15/23 |
| EPS | $-0.46 | – |
| Book Value/Share | $1.03 | – |
| FCF/Share | $-0.41 | – |
Profitability & Margins
| Metric | NAUT | Rank |
|---|---|---|
| ROE | -43.1% | 14/20 |
| ROA | -34.5% | 15/20 |
Financial Health
| Metric | NAUT | Rank |
|---|---|---|
| Current Ratio | 10.14x | 4/25 |
| Quick Ratio | 10.07x | 3/24 |
| D/E Ratio | 0.25x | 19/24 |
| Financial Leverage | 1.25x | 19/23 |
| Working Capital | $79M | 17/25 |
Cash Flow
| Metric | NAUT | Rank |
|---|---|---|
| Operating Cash Flow | -$50M | 21/24 |
| Free Cash Flow | -$52M | 17/20 |
| Capital Spending | -$2M | 8/20 |
Income Statement
| Metric | NAUT | Rank |
|---|---|---|
| Net Income | -$57M | 13/21 |
| R&D Expense | $38M | 11/21 |
Dividend & Shareholder Information
| Metric | NAUT | Rank |
|---|---|---|
| Shares Outstanding | 127M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $88M | 53.6% of assets |
| Cash & Short-term Investments | $13M | 8.1% of assets |
| Inventory | $600K | 0.4% of assets |
| Total Liabilities | $32M | 19.8% of assets |
| Short-term Debt | $8M | 4.6% of assets |
Quarterly Financial Reports
NAUT quarterly financials and insider trading
Industry Peers · Laboratory Analytical Instruments
Nautilus Biotechnology, Inc. (NAUT) industry peers
Companies classified under the same SEC industry code as Nautilus Biotechnology, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| NAUT Nautilus Biotechnology, Inc. | ▲ | $262M |
| A Agilent Technologies, Inc. | ▼ | $48.75B |
| WAT Waters Corp /De/ | ▶ | $42.93B |
| ILMN Illumina, Inc. | ▲ | $39.64B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.51B |
| RVTY Revvity, Inc. | ▶ | $17.03B |
| AVTR Avantor, Inc. | ▼ | $11.19B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.46B |
| TXG 10x Genomics, Inc. | ▲ | $9.10B |
| BRKR Bruker Corp | ▲ | $8.35B |
| ALMR Alamar Biosciences, Inc. | ▲ | $1.75B |
| CTKB Cytek Biosciences, Inc. | ▲ | $682M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $538M |
| MASS 908 Devices Inc. | ▲ | $465M |
| EYPT Eyepoint, Inc. | ▲ | $258M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $235M |
| QTRX Quanterix Corp | ▲ | $136M |
| SEER Seer, Inc. | ▲ | $113M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $42M |
| PRPO Precipio, Inc. | ▶ | $38M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $15M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $10M |
| SCND Scientific Industries Inc | ▶ | $8M |
Where NAUT sits on the market map
Industrial Applications and Services · Laboratory Analytical Instruments
News
Nautilus Biotechnology, Inc. (NAUT) stock news
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being ...
FAQ
Nautilus Biotechnology, Inc. (NAUT) stock forecast FAQ
What is the Nautilus Biotechnology, Inc. (NAUT) stock forecast?
Our AI ranks Nautilus Biotechnology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Nautilus Biotechnology, Inc. stock predictions?
For NAUT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 8.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Nautilus Biotechnology, Inc. forecasts updated?
Nautilus Biotechnology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Nautilus Biotechnology, Inc.'s industry peers?
25 issuers in our coverage, NAUT included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.